Literature DB >> 10831463

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

E Dieperink1, M Willenbring, S B Ho.   

Abstract

OBJECTIVE: Neuropsychiatric symptoms are commonly associated with chronic hepatitis C virus infection, its sequelae, and its treatment. In particular, interferon, a primary component of treatment for chronic hepatitis C, has been strongly associated with depressive symptoms. This review summarizes current knowledge about the etiology, course, and treatment of neuropsychiatric problems associated with hepatitis C and interferon alpha (IFN-alpha) treatment.
METHOD: Studies were identified by computerized searches, and further references were obtained from bibliographies of the reviewed articles.
RESULTS: Chronic infection with the hepatitis C virus is a common and growing problem, often affecting persons with psychiatric and substance use problems. Although changes in cognition, mood, and personality have been described in association with hepatitis C and with IFN-alpha treatment, there has been little systematic study of these changes.
CONCLUSIONS: Psychiatrists should become familiar with the clinical spectrum associated with hepatitis C virus infection as well as the neuropsychiatric symptoms related to hepatitis C and IFN-alpha treatment. More studies are necessary to define the neuropsychiatric syndromes associated with this population and to find possible effective treatments. Furthermore, research is needed so that patients with psychiatric problems are not excluded from effective treatments for this growing medical problem.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831463     DOI: 10.1176/appi.ajp.157.6.867

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  99 in total

1.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Authors:  Joseph Rasimas; Antonios Katsounas; Haniya Raza; Alison A Murphy; Jun Yang; Richard A Lempicki; Anu Osinusi; Henry Masur; Michael Polis; Shyam Kottilil; Donald Rosenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

3.  A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.

Authors:  Amira Pierucci-Lagha; Jonathan Covault; Herbert L Bonkovsky; Richard Feinn; Christine Abreu; Richard K Sterling; Robert J Fontana; Henry R Kranzler
Journal:  Psychosomatics       Date:  2010 Mar-Apr       Impact factor: 2.386

4.  Interferon-alpha induced mania during the adjuvant treatment of malignant melanoma.

Authors:  A M Ni Mhaolain; J H Thakore
Journal:  Ir J Med Sci       Date:  2007-03-30       Impact factor: 1.568

Review 5.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

6.  Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Authors:  Ondria C Gleason; William R Yates; Michelle A Philipsen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

7.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

8.  Simian immunodeficiency virus infection in the brain and lung leads to differential type I IFN signaling during acute infection.

Authors:  Luna Alammar; Lucio Gama; Janice E Clements
Journal:  J Immunol       Date:  2011-03-02       Impact factor: 5.422

9.  Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.

Authors:  Péter Kovács; Gitta Pánczél; Kinga Borbola; Gabriella Juhász; Gabriella Liszkay
Journal:  Pathol Oncol Res       Date:  2014-04-27       Impact factor: 3.201

10.  Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.

Authors:  Adam Isaiah Newman; Shelley Beckstead; David Beking; Susan Finch; Tina Knorr; Carol Lynch; Meredith MacKenzie; Daphne Mayer; Brenda Melles; Ron Shore
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.